Baseline clinical and biological characteristics in EBV+ DLBCL-NOS patients, according to age group
| Characteristic . | EBV+ DLBCL-NOS . | ≤50 y . | >50 y . | P . | |
|---|---|---|---|---|---|
| Total, n | 70 | 23 | 47 | ||
| Age (y), median (range) | 68.5 (16 – 103) | 37 (16 – 50) | 74 (50 – 103) | ||
| Male | 44 (63) | 14 (61) | 30 (64) | >.99 | |
| Female | 26 (37) | 9 (39) | 17 (36) | ||
| Involved site, n | 67 | 23 | 44 | ||
| Nodal | 64 (96) | 23 (100) | 41 (93) | .546 | |
| Extranodal | 32 (48) | 7 (30) | 25 (57) | .070 | |
| 1 | 15 (22) | 3 (13) | 12 (27) | ||
| ≥2 | 17 (25) | 4 (17) | 13 (30) | ||
| Clinical stage, n | 67 | 23 | 44 | ||
| I-II | 14 (21) | 7 (30) | 7 (16) | .210 | |
| III-IV | 53 (79) | 16 (70) | 37 (84) | ||
| aaIPI, n | 58 | 22 | 36 | ||
| 0-1 | 16 (28) | 10 (45) | 6 (17) | .032 | |
| 2-3 | 42 (72) | 12 (55) | 30 (83) | ||
| ECOG-PS, n | 66 | 23 | 43 | ||
| 0-1 | 30 (46) | 19 (83) | 11 (26) | <.001 | |
| 2-5 | 36 (54) | 4 (17) | 32 (74) | ||
| B symptoms, n | 65 | 23 | 42 | ||
| Absent | 15 (23) | 6 (26) | 9 (21) | .761 | |
| Present | 50 (77) | 17 (74) | 33 (79) | ||
| LDH, n | 58 | 22 | 36 | ||
| Normal | 15 (26) | 6 (27) | 9 (25) | >.99 | |
| High | 43 (74) | 16 (73) | 27 (75) | ||
| Lymphopenia, n | 52 | 19 | 33 | ||
| Absent | 17 (33) | 7 (37) | 10 (30) | .761 | |
| Present | 35 (67) | 12 (63) | 23 (70) | ||
| HLH, n | 65 | 23 | 42 | ||
| Absent | 56 (86) | 21 (91) | 35 (83) | .473 | |
| Present | 9 (14) | 2 (9) | 7 (17) | ||
| Histological pattern | 67 | 23 | 44 | ||
| Monomorphic | 21 (31) | 6 (26) | 15 (34) | .587 | |
| Polymorphic | 46 (69) | 17 (74) | 29 (66) | ||
| EBV serology | 21 | 7 | 14 | ||
| Past infection (IgG+ EBV−VCA, IgM− EBV−VCA, IgG+ EBNA1) | 21 (100) | 7 (100) | 14 (100) | >.99 | |
| EBV viral load | 16 | 5 | 11 | ||
| Positive | 11 (69) | 3 (60) | 8 (73) | >.99 | |
| Negative | 2 (31) | 2 (40) | 3 (27) | ||
| EBV latency | 57 | 21 | 36 | ||
| Type II (LMP1+/EBNA2−) | 50 (88) | 18 (86) | 32 (89) | .701 | |
| Type III (LMP1+/EBNA2+) | 7 (12) | 3 (14) | 4 (11) | ||
| Characteristic . | EBV+ DLBCL-NOS . | ≤50 y . | >50 y . | P . | |
|---|---|---|---|---|---|
| Total, n | 70 | 23 | 47 | ||
| Age (y), median (range) | 68.5 (16 – 103) | 37 (16 – 50) | 74 (50 – 103) | ||
| Male | 44 (63) | 14 (61) | 30 (64) | >.99 | |
| Female | 26 (37) | 9 (39) | 17 (36) | ||
| Involved site, n | 67 | 23 | 44 | ||
| Nodal | 64 (96) | 23 (100) | 41 (93) | .546 | |
| Extranodal | 32 (48) | 7 (30) | 25 (57) | .070 | |
| 1 | 15 (22) | 3 (13) | 12 (27) | ||
| ≥2 | 17 (25) | 4 (17) | 13 (30) | ||
| Clinical stage, n | 67 | 23 | 44 | ||
| I-II | 14 (21) | 7 (30) | 7 (16) | .210 | |
| III-IV | 53 (79) | 16 (70) | 37 (84) | ||
| aaIPI, n | 58 | 22 | 36 | ||
| 0-1 | 16 (28) | 10 (45) | 6 (17) | .032 | |
| 2-3 | 42 (72) | 12 (55) | 30 (83) | ||
| ECOG-PS, n | 66 | 23 | 43 | ||
| 0-1 | 30 (46) | 19 (83) | 11 (26) | <.001 | |
| 2-5 | 36 (54) | 4 (17) | 32 (74) | ||
| B symptoms, n | 65 | 23 | 42 | ||
| Absent | 15 (23) | 6 (26) | 9 (21) | .761 | |
| Present | 50 (77) | 17 (74) | 33 (79) | ||
| LDH, n | 58 | 22 | 36 | ||
| Normal | 15 (26) | 6 (27) | 9 (25) | >.99 | |
| High | 43 (74) | 16 (73) | 27 (75) | ||
| Lymphopenia, n | 52 | 19 | 33 | ||
| Absent | 17 (33) | 7 (37) | 10 (30) | .761 | |
| Present | 35 (67) | 12 (63) | 23 (70) | ||
| HLH, n | 65 | 23 | 42 | ||
| Absent | 56 (86) | 21 (91) | 35 (83) | .473 | |
| Present | 9 (14) | 2 (9) | 7 (17) | ||
| Histological pattern | 67 | 23 | 44 | ||
| Monomorphic | 21 (31) | 6 (26) | 15 (34) | .587 | |
| Polymorphic | 46 (69) | 17 (74) | 29 (66) | ||
| EBV serology | 21 | 7 | 14 | ||
| Past infection (IgG+ EBV−VCA, IgM− EBV−VCA, IgG+ EBNA1) | 21 (100) | 7 (100) | 14 (100) | >.99 | |
| EBV viral load | 16 | 5 | 11 | ||
| Positive | 11 (69) | 3 (60) | 8 (73) | >.99 | |
| Negative | 2 (31) | 2 (40) | 3 (27) | ||
| EBV latency | 57 | 21 | 36 | ||
| Type II (LMP1+/EBNA2−) | 50 (88) | 18 (86) | 32 (89) | .701 | |
| Type III (LMP1+/EBNA2+) | 7 (12) | 3 (14) | 4 (11) | ||
Data are presented as n (%) of patients, unless otherwise indicated.
aaIPI, age-adjusted International Prognostic Index; ECOG-PS, Eastern Cooperative Oncology Group performance status; HLH, hemophagocytic lymphohistiocytosis; RT, radiation therapy; VCA, viral capsid antigen.